January 31, 2020 / 11:50 AM / 20 days ago

European drug panel recommends approval for Novo Nordisk oral diabetes treatment

Jan 31 (Reuters) - A panel of the European medicines regulator has recommended approving Novo Nordisk’s new diabetes pill, Rybelsus, further boosting prospects for the Danish drugmaker with its first-of-a-kind, non-injectable treatment.

The European Medicines Agency said here its human medicines committee adopted a positive opinion on the treatment, chemically called semaglutide, for the treatment of type-2 diabetes - the most common form of the disease.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Krishna Chandra Eluri

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below